The makers or popular opioid drugs like OxyContin and Fentanyl may face a class action in Australia by consumers who allege they suffered financial loss from the addictive drugs.
The Australian Competition and Consumer Commission has taken swift action to allow medical technology companies to coordinate on supplying ventilators, protective gear and other equipment in high demand due to the coronavirus.
Generic drug maker Juno Pharmaceuticals has agreed to stopped planned sales of its cheap version of Millennium Pharmaceuticals anti-cancer medication Velcade in Australia as part of a settlement of its lawsuit alleging two patents covering the drug were invalid.
AFT Pharmaceuticals has lost its challenge to a ruling that ads claiming its painkiller Maxigesic is more effective than Nuremol were misleading and deceptive, with the Full Federal Court saying the primary judge did not err in finding the ads lacked an adequate scientific basis.
The Australian Competition and Consumer Commission has issued guidelines on consumers’ rights to refunds if a flight or event is shuttered due to the coronavirus, saying consumer guarantees could be affected if cancellation are caused by government restrictions.
A Federal Court judge has acknowledged concerns raised by the accused in a criminal cartel case against mobility equipment provider Country Care and two employees about how an upcoming jury trial will proceed if the coronavirus pandemic worsens, telling the parties the court had already taken measures to control the spread of the virus.
A court has tossed a case by the ACCC against Ramsay Health Care claiming that the global hospital group misused its market power by pressuring a group of doctors who planned to open their own day clinic.
A judge has ordered Johnson & Johnson to include a graphic warning on the patient information leaflets and instructions for use that accompany four of its pelvic mesh products, following a class action over the devices which saw the three lead applicants awarded $2.6 million in damages.
A Federal Court judge has awarded combined damages of $2.6 million to the lead applicants in the Johnson & Johnson pelvic mesh class action, following a landmark ruling in November which found that the pharmaceutical giant did not adequately warn of the risks of the implants.
A judge has granted a request by Otsuka and Bristol-Myers Squibbs to withdraw admissions in proceedings brought by Generic Health seeking damages, after the generic drug maker was temporarily blocked from selling a generic version of antipsychotic Abilify in a patent dispute in which it ultimately triumphed.